Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Price & Analysis

Compare

1 Followers

6990 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$120.20 - HK$365.00

Previous CloseN/A

Volume210.00K

Average Volume (3M)681.13K

Market Cap

HK$75.41B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Sep 01, 2025

EPS Estimate

-0.65

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.64

Shares Outstanding156,851,970

10 Day Avg. Volume868,394

30 Day Avg. Volume681,126

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$305.31

Price Target Upside-7.98% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H News

PremiumCompany Announcements

Sichuan Kelun-Biotech Announces New H Shares Placing and Articles Amendment

4d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Announces AGM Shareholder Register Closure

10d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Receives Upfront Payment in License Agreement with Windward Bio

17d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech to Present Promising Cancer Drug Results at ASCO 2025

17d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech’s New Breast Cancer Treatment Application Accepted by NMPA

18d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Announces 2025 AGM Agenda

19d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Enhances Governance with New Remuneration Committee

25d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Enhances Governance with New Audit Committee

25d ago

6990

See All HK:6990 News

See All News >

Bulls Say, Bears Say

Bulls Say

Commercial ExpansionSignificant strides in commercialization with three commercialized assets and plans to expand the commercial team to 500+ employees by 2Q25.

Financial PerformanceKelun-Biotech reported strong financial results for 2024, driven by milestone payments from global collaborations and the progression of its innovative pipeline.

Innovative Product DevelopmentSKB378's extended half-life allows dosing every six months, a significant improvement over the currently approved TSLP mAb, which requires administration every four weeks.

Strategic PartnershipsLicensing and collaboration agreements contributed RMB 1.86bn revenue, reflecting strong partnerships, particularly milestone payments from MSD.

Bears Say

Competitive MarketThe TSLP-targeted therapy space continues to see active transactions, indicating growing momentum in this area.

Net Loss ConcernsThe Company narrowed its net loss significantly to RMB 266.8mn, an improvement from RMB 574.1mn in 2023, as revenue growth outpaced cost expansion.

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.02%

Mutual Funds

― Other Institutional Investors

97.93% Public Companies and

Individual Investors

Detailed Ownership Overview >

6990 FAQ

What was Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$120.20 and its highest was HK$365.00 in the past 12 months.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap is HK$75.41B.

When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2025 which is in 84 days.

How were Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 24, 2025. The company reported -HK$2.641 earnings per share for the quarter, beating the consensus estimate of -HK$2.748 by HK$0.107.

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H overvalued?

According to Wall Street analysts Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pay dividends?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate is -0.65.

How many shares outstanding does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H have?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 156,851,970 shares outstanding.

What happened to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$2.641 in its last earnings report, beating expectations of -HK$2.748. Following the earnings report the stock price went up 0.231%.

Which hedge fund is a major shareholder of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Stock Smart Score

Outperform

Fundamentals

Return on Equity

-9.52%

Trailing 12-Months

Asset Growth

17.54%

Trailing 12-Months

Top Smart Score Stocks >

6990 Stock 12 Month Forecast

Average Price Target

HK$305.31

▼(-7.98%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"HK$75","196":"HK$196","317":"HK$317","135.5":"HK$135.5","256.5":"HK$256.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":316,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$316.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":305.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$305.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":299.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$299.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,135.5,196,256.5,317],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Jun<br/>2024","9":"Nov<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,231,237.53846153846155,244.07692307692307,250.6153846153846,257.15384615384613,263.6923076923077,270.2307692307692,276.7692307692308,283.3076923076923,289.84615384615387,296.38461538461536,302.9230769230769,309.46153846153845,{"y":316,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,231,236.71615384615384,242.4323076923077,248.14846153846153,253.86461538461538,259.58076923076925,265.29692307692306,271.01307692307694,276.72923076923075,282.4453846153846,288.16153846153844,293.8776923076923,299.59384615384613,{"y":305.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,231,236.3023076923077,241.60461538461539,246.90692307692308,252.20923076923077,257.51153846153846,262.81384615384616,268.11615384615385,273.41846153846154,278.72076923076924,284.0230769230769,289.3253846153846,294.6276923076923,{"y":299.93,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.1,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":76.5,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":76.6,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":83,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":83,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.7,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >